看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | -1.5x - -1.6x | -1.5x |
| Historical Pb Multiple | -2.9x - 4.0x | 2.1x |
| Fair Value | $0.028 - $0.030 | $0.029 |
| Upside | -44.8% - -39.0% | -41.9% |
| Benchmarks | - | Full Ticker |
| 4Front Ventures Corp. | - | CNSX:FFNT |
| Harmony Biosciences Holdings, Inc. | - | NasdaqGM:HRMY |
| Evolus, Inc. | - | NasdaqGM:EOLS |
| Tarsus Pharmaceuticals, Inc. | - | NasdaqGS:TARS |
| Bio Essence Corporation | - | OTCPK:BIOE |
| FLUENT Corp. | - | CNSX:FNT.U |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| FFNT | HRMY | EOLS | TARS | BIOE | FNT.U | |||
| CNSX:FFNT | NasdaqGM:HRMY | NasdaqGM:EOLS | NasdaqGS:TARS | OTCPK:BIOE | CNSX:FNT.U | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | 61.4% | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | 31.3% | 12.9% | 18.3% | 15.0% | -287.0% | -77.5% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -170.4% | -20.1% | -93.5% | -276.4% | -170.1% | -54.2% | ||
| Prior Fiscal Year | -19.8% | 22.1% | -30.5% | -778.9% | NA | -23.4% | ||
| Latest Fiscal Year | -45.9% | 20.4% | -18.9% | -63.2% | -483.3% | -39.0% | ||
| Latest Twelve Months | -46.6% | 20.4% | -18.9% | -63.2% | -483.3% | -39.0% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | -237.0% | 14.7% | -433.2% | -38.9% | NA | -134.2% | ||
| Prior Fiscal Year | -64.9% | 29.6% | -666.9% | -69.7% | NM | -125.9% | ||
| Latest Twelve Months | NM | 25.8% | -1826.1% | -54.8% | NM | -940.9% | ||
| Next Fiscal Year | 82.7% | 30.3% | -162.1% | -18.8% | #NUM! | 171.5% | ||
| Two Fiscal Years Forward | -190.2% | 29.3% | 204.8% | 29.6% | 96.0% | 72.9% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 0.0x | 2.3x | 2.5x | 11.0x | 24.2x | 0.3x | ||
| Price / LTM EPS | -0.1x | 11.2x | -13.1x | -17.5x | -5.0x | -0.6x | ||
| Price / Book | -0.1x | 2.5x | 119.5x | 9.0x | -2.6x | -2.9x | ||
| Price / Fwd Book | 0.0x | 1.8x | 21291.3x | 10.8x | -2.6x | -0.2x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | -2.6x | 2.5x | 119.5x | |||||
| Historical P/B Ratio | -2.9x | 2.1x | 4.0x | |||||
| Selected P/B Multiple | -1.5x | -1.5x | -1.6x | |||||
| (x) Book Value | (9) | (9) | (9) | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | FFNT | HRMY | EOLS | TARS | BIOE | FNT.U | |
| Value of Common Equity | 3 | 1,636 | 660 | 2,018 | 8 | 24 | |
| (/) Shares Outstanding | 916.4 | 57.4 | 63.6 | 41.6 | 38.0 | 472.3 | |
| Implied Stock Price | 0.00 | 28.50 | 10.38 | 48.51 | 0.21 | 0.05 | |
| FX Conversion Rate to Trading Currency | 0.72 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 0.01 | 28.50 | 10.38 | 48.51 | 0.21 | 0.05 | |
| Trading Currency | CAD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 0.72 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |